Search

Your search keyword '"Kirby, Adrienne"' showing total 5 results
Start Over Author "Kirby, Adrienne" Journal bmj open
5 results on '"Kirby, Adrienne"'

1. Pregnancy outcomes in women with gestational diabetes mellitus by models of care: a retrospective cohort study

Author

Harrison, Jackson, primary, Melov, Sarah, additional, Kirby, Adrienne C, additional, Athayde, Neil, additional, Boghossian, Araz, additional, Cheung, Wah, additional, Inglis, Emma, additional, Maravar, Kavita, additional, Padmanabhan, Suja, additional, Luig, Melissa, additional, Hook, Monica, additional, and Pasupathy, Dharmintra, additional

Published
2022
Full Text
View/download PDF

2. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)

Author

Mersiades, Antony J, primary, Tognela, Annette, additional, Haber, Paul S, additional, Stockler, Martin, additional, Lintzeris, Nicholas, additional, Simes, John, additional, McGregor, Iain, additional, Olver, Ian, additional, Allsop, David J, additional, Gedye, Craig, additional, Kirby, Adrienne C, additional, Morton, Rachael L, additional, Fox, Peter, additional, Clarke, Stephen, additional, Briscoe, Karen, additional, Aghmesheh, Morteza, additional, Wong, Nicole, additional, Walsh, Anna, additional, Hahn, Carmel, additional, and Grimison, Peter, additional

Published
2018
Full Text
View/download PDF

4. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)

Author

Ian N. Olver, Adrienne Kirby, Stephen Clarke, Carmel Hahn, Nicholas Lintzeris, Paul S. Haber, Craig Gedye, Anna Walsh, Morteza Aghmesheh, Karen Briscoe, Peter Grimison, John Simes, Annette Tognela, David J. Allsop, Peter Fox, Antony Mersiades, Martin R. Stockler, Nicole Wong, Rachael L. Morton, Iain S. McGregor, Mersiades, Antony J, Tognela, Annette, Haber, Paul S, Stockler, Martin, Lintzeris, Nicholas, Simes, John, McGregor, Iain, Olver, Ian, Allsop, David J, Gedye, Craig, Kirby, Adrienne C, Morton, Rachael L, Fox, Peter, Clarke, Stephen, Briscoe, Karen, Aghmesheh, Morteza, Wong, Nicole, Walsh, Anna, Hahn, Carmel, and Grimison, Peter

Subjects
cannabis, medicine.medical_specialty, Vomiting, Nausea, medicine.drug_class, Cost-Benefit Analysis, Placebo-controlled study, Administration, Oral, Antineoplastic Agents, Pilot Projects, Oral cannabinoid-rich THC/CBD, law.invention, cannabidiol, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, law, Internal medicine, randomized trial, Secondary Prevention, medicine, Cannabidiol, Humans, Multicenter Studies as Topic, Antiemetic, chemotherapy-induced nausea and vomiting, Dronabinol, Patient Reported Outcome Measures, 030212 general & internal medicine, Adverse effect, Randomized Controlled Trials as Topic, Cannabinoid Receptor Agonists, business.industry, antiemetic, General Medicine, Drug Combinations, Regimen, Tolerability, 030220 oncology & carcinogenesis, prevention of chemotherapy-induced nausea and vomiting, medicine.symptom, business, Phytotherapy, Chemotherapy-induced nausea and vomiting
Abstract

IntroductionChemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, significant adverse events and flawed study design. Trials using cannabidiol-rich (CBD) products demonstrate improved efficacy and psychological adverse event profile. No definitive trials have been conducted to support the use of cannabinoids for this indication, nor has the potential economic impact of incorporating such regimens into the Australian healthcare system been established. CannabisCINV aims to assess the efficacy, safety and cost-effectiveness of adding TN-TC11M, an oral THC/CBD extract to guideline-consistent antiemetics in the secondary prevention of CINV.Methods and analysisThe current multicentre, 1:1 randomised cross-over, placebo-controlled pilot study will recruit 80 adult patients with any malignancy, experiencing CINV during moderate to highly emetogenic chemotherapy despite guideline-consistent antiemetics. Patients receive oral TN-TC11M (THC 2.5mg/CBD 2.5 mg) capsules or placebo capsules three times a day on day −1 to day 5 of cycle A of chemotherapy, followed by the alternative drug regimen during cycle B of chemotherapy and the preferred drug regimen during cycle C. The primary endpoint is the proportion of subjects attaining a complete response to CINV. Secondary and tertiary endpoints include regimen tolerability, impact on quality of life and health system resource use. The primary assessment tool is patient diaries, which are filled from day −1 to day 5. A subsequent randomised placebo-controlled parallel phase III trial will recruit a further 250 patients.Ethics and disseminationThe protocol was approved by ethics review committees for all participating sites. Results will be disseminated in peer-reviewed journals and at scientific conferences.Drug supplyTilray.Protocol version2.0, 9 June 2017.Trial registration numberANZCTR12616001036404; Pre-results.

Published
2018

5. Harnessing neuroplasticity to improve motor performance in infants with cerebral palsy: a study protocol for the GAME randomised controlled trial.

Author

Morgan C, Badawi N, Boyd RN, Spittle AJ, Dale RC, Kirby A, Hunt RW, Whittingham K, Pannek K, Morton RL, Tarnow-Mordi W, Fahey MC, Walker K, Prelog K, Elliott C, Valentine J, Guzzetta A, Olivey S, and Novak I

Subjects
Child, Infant, Newborn, Humans, Infant, Quality of Life, Australia, Cognition, Neuronal Plasticity, Randomized Controlled Trials as Topic, Cerebral Palsy psychology
Abstract

Introduction: Cerebral palsy (CP) is the most common physical disability of childhood worldwide. Historically the diagnosis was made between 12 and 24 months, meaning data about effective early interventions to improve motor outcomes are scant. In high-income countries, two in three children will walk. This evaluator-blinded randomised controlled trial will investigate the efficacy of an early and sustained Goals-Activity-Motor Enrichment approach to improve motor and cognitive skills in infants with suspected or confirmed CP., Methods and Analysis: Participants will be recruited from neonatal intensive care units and the community in Australia across four states. To be eligible for inclusion infants will be aged 3-6.5 months corrected for prematurity and have a diagnosis of CP or 'high risk of CP' according to the International Clinical Practice Guideline criteria. Eligible participants whose caregivers consent will be randomly allocated to receive usual care or weekly sessions at home from a GAME-trained study physiotherapist or occupational therapist, paired with a daily home programme, until age 2. The study requires 150 participants per group to detect a 0.5 SD difference in motor skills at 2 years of age, measured by the Peabody Developmental Motor Scales-2. Secondary outcomes include gross motor function, cognition, functional independence, social-emotional development and quality of life. A within-trial economic evaluation is also planned., Ethics and Dissemination: Ethical approval was obtained from the Sydney Children's Hospital Network Human Ethics Committee in April 2017 (ref number HREC/17/SCHN/37). Outcomes will be disseminated through peer-reviewed journal publications, presentations at international conferences and consumer websites., Trial Registration Number: ACTRN12617000006347., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results